where do you get tirzepatide / Niacinamide Injection Tirzepatide Injection for Weight Loss

In SURPASS-2, tirzepatide caused vomiting in 6-10% of participants across dose levels, while semaglutide 1 mg caused vomiting in 8%

Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg for 4 weeks and then gradually titrated upward based on individual response and tolerability

In otherwise healthy patients with incidental neutropenia, the physical examination should focus on examination for adenopathy or splenomegaly, as well as specific signs of active or prior infection, such as healing skin ulcers or aphthous ulcers

There is currently no established causal relationship between tirzepatide and tooth decay based on available clinical trial data and FDA-approved prescribing information

The most commonly reported adverse effects are gastrointestinal, such as nausea or diarrhea